Nautilus Biotechnology, Inc.
NAUTNautilus Biotechnology is a development-stage life sciences company creating a platform technology to quantify and unlock the complexity of the proteome.
Earnings
Q3 2026 report
October 27, 2026Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Nautilus Biotechnology is a development-stage life sciences company creating a platform technology to quantify and unlock the complexity of the proteome. The company's core value proposition is its 'Iterative Mapping' method, which enables the analysis of single, intact protein molecules at scale to provide broad, deep, and highly reproducible proteomic data. This platform is designed to overcome the limitations of traditional mass spectrometry and affinity-based technologies in drug discovery and precision medicine.
Nautilus is a development-stage challenger seeking to disrupt the proteomics market by offering a single-molecule measurement paradigm that avoids the trade-offs of existing mass spectrometry and affinity-based methods.
FAQ
- What is Nautilus Biotechnology, Inc.'s market cap?
- Nautilus Biotechnology, Inc. (NAUT) has a market capitalization of $399.9M and trades on NASDAQ.
- Who are Nautilus Biotechnology, Inc.'s competitors?
- Nautilus Biotechnology, Inc.'s key competitors include Quantum-Si Incorporated, Seer, Inc. Class A Common Stock, Thermo Fisher Scientific Inc., and others. These companies compete in similar markets and product categories.
- What subsidiaries does Nautilus Biotechnology, Inc. have?
- Nautilus Biotechnology, Inc.'s subsidiaries include Nautilus Subsidiary, Inc..
- Where is Nautilus Biotechnology, Inc. headquartered?
- Nautilus Biotechnology, Inc. is headquartered in United States of America and employs approximately 163 people. It has been publicly traded since 2021.